Eosinophilic oesophagitis

7 trials 4 recruiting MedDRA PT
7 Registered trials
4 Recruiting
5 Unique sponsors
4 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Corticosteroid 1 substance
Phase III: 1 Phase II: 2 Phase I: 1 Phase I (Other): 3

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

1 trial
  • Dr. Falk Pharma GmbH Commercial
    BUDESONIDE
    2024-515229-26-00 4 countries 2021 n=234 Orphan
    Recruiting

Phase II

2 trials
  • Bioprojet Pharma Commercial
    BP1.7881A
    2023-508949-40-00 2 countries 2024 n=24
    Recruiting
  • NI One Inc. Commercial
    SOLRIKITUG
    2024-510849-34-00 5 countries 2025 n=49
    Ended

Phase I

1 trial
  • Anaptysbio Inc. Commercial
    IMP not specified
    2024-520409-38-00 3 countries 2025 n=25
    Recruiting

Phase I (Other)

3 trials
  • Bioprojet Pharma Commercial
    IMP not specified
    2024-512722-28-00 1 country 2025 n=161
    Recruiting
  • Pfizer Inc. Commercial
    ETRASIMOD ARGININE
    2023-504411-32-00 1 country 2023 n=16
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-508119-22-00 1 country 2023 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bioprojet Pharma Commercial 2 Phase I (Other), Phase II 2
Pfizer Inc. Commercial 2 Phase I (Other) 0
Anaptysbio Inc. Commercial 1 Phase I 1
NI One Inc. Commercial 1 Phase II 0
Dr. Falk Pharma GmbH Commercial 1 Phase III 1
New trials by year
2021
1
2023
2
2024
1
2025
3
← All indication landscapes